Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Clinical trial NCT07030140 · RECRUITING

Trial details

NCT number: NCT07030140
Sponsor: Jinbo Yue
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cholangiocarcinoma Hilar Cholangiocarcinoma Bile Duct Cancer

Start date: 2025-07-01
Primary completion: 2027-07-01
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.